Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients

Lung Cancer

Volumn 62, Issue 2, 2008, Pages 193-201

  Reinmuth, Niels ^a   Jauch, Anna ^b   Xu, Elizabeth Chang ^a   Muley, Thomas ^a   Granzow, Martin ^b,c   Hoffmann, Hans ^a   Dienemann, Hendrik ^a   Herpel, Esther ^d   Schnabel, Philipp A ^d   Herth, Felix J F ^a   Gottschling, Sandra ^a   Lahm, Harald ^a   Steins, Martin ^a   Thomas, Michael ^a   Meister, Michael ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c Quantiom Bioinformatics GmbH and Co KG   (Germany)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Adenocarcinoma; Comparative genomic hybridization; EGFR mutation; Immunohistochemistry; Non small cell lung cancer; VEGF expression

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 3; VASCULOTROPIN;

ARTICLE; CANCER PATIENT; CHROMOSOME 16P; CHROMOSOME 20P; CHROMOSOME 7P; CHROMOSOME 8P; CHROMOSOME ABERRATION; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DNA SEQUENCE; EXON; FEMALE; GENE MUTATION; GENETIC SCREENING; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG ALVEOLUS CELL CARCINOMA; MALE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; TUMOR DIFFERENTIATION; WILD TYPE;

ADENOCARCINOMA; CHROMOSOME ABERRATIONS; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MUTATIONAL ANALYSIS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MUTATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-3; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 55049122814     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.03.011     Document Type: Article

References (41)

1. Yarden Y., and Sliwkowski M.X. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2 (2001) 127-137
2. Reinmuth N., Brandt B., Kunze W.P., Junker K., Thomas M., Achatzy R., et al. expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer. Eur Respir J 16 (2000) 991-996
3. Hirsch F.R., Varella-Garcia M., Franklin W.A., Veve R., Chen L., Helfrich B., et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer 86 (2002) 1449-1456
4. Akita R.W., and Sliwkowski M.X. Preclinical studies with Erlotinib (Tarceva). Semin Oncol 30 (2003) 15-24
5. Shepherd F.A., Pereira J.R., Ciuleanu T.E., Tan E.H., Hirsh V., Thongprasert S., et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 353 (2005) 123-132
6. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 (2005) 341-354
7. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97 (2005) 643-655
8. Tsao M.-S., Sakurada A., Cutz J.-C., Zhu C.-Q., Kamel-Reid S., Squire J., et al. Erlotinib in lung cancer--molecular and clinical predictors of outcome. N Engl J Med 353 (2005) 133-144
9. Taron M., Ichinose Y., Rosell R., Mok T., Massuti B., Zamora L., et al. Activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor are associated with improved survival in Gefitinib-treated chemorefractory lung adenocarcinomas. Clin Cancer Res 11 (2005) 5878-5885
10. Reinmuth N., Meister M., Muley T., Steins M., Kreuter M., Herth F.J., et al. Molecular determinants of response to RTK-targeting agents in nonsmall cell lung cancer. Int J Cancer 119 (2006) 727-734
11. Pao W., Wang T.Y., Riely G.J., Miller V.A., Pan Q., Ladanyi M., et al. Primary resistance of lung adenocarcinomas to Gefitinib or Erlotinib. PLoS Med 2 (2005) e17
12. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350 (2004) 2129-2139
13. Sordella R., Bell D.W., Haber D.A., and Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305 (2004) 1163-1167
14. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., et al. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102 (2005) 3788-3793
15. Akagi M., Kawaguchi M., Liu W., McCarty M.F., Takeda A., Fan F., et al. Induction of neuropilin-1 and vascular endothelial growth factor by epidermal growth factor in human gastric cancer cells. Br J Cancer 88 (2003) 796-802
16. Clarke K., Smith K., Gullick W.J., and Harris A.L. Mutant epidermal growth factor receptor enhances induction of vascular endothelial growth factor by hypoxia and insulin-like growth factor-1 via a PI3 kinase dependent pathway. Br J Cancer 84 (2001) 1322-1329
17. Fidler I.J., and Ellis L.M. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 79 (1994) 185-188
18. World Health Organization. Histological Typing of Lung Tumours. 3rd ed. Lyon: IARC Press; 2004.
19. Meister M., Schirmacher P., Dienemann H., Mechtersheimer G., Schnabel P.A., Kern M.A., et al. Mutational status of the epidermal growth factor receptor (EGFR) gene in thymomas and thymic carcinomas. Cancer Lett 248 (2007) 186-191
20. du Manoir S., Speicher M.R., Joos S., Schrock E., Popp S., Dohner H., et al. Detection of complete and partial chromosome gains and losses by comparative genomic in situ hybridization. Hum Genet 90 (1993) 590-610
21. Kallioniemi O.P., Kallioniemi A., Piper J., Isola J., Waldman F.M., Gray J.W., et al. Optimizing comparative genomic hybridization for analysis of DNA sequence copy number changes in solid tumors. Genes Chromosomes Cancer 10 (1994) 231-243
22. Reinmuth N., Piegelbrock E., Raedel M., Fehrmann N., Hintelmann H., Wagner R., et al. Prognostic significance of vessel architecture and vascular stability in non-small cell lung cancer. Lung Cancer 55 (2007) 53-60
23. Schmidt-Kittler O., Ragg T., Daskalakis A., Granzow M., Ahr A., Blankenstein T.J., et al. From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100 (2003) 7737-7742
24. Schroeder A., Mueller O., Stocker S., Salowsky R., Leiber M., Gassmann M., et al. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 7 (2006) 3
25. Ragg T., and Bayesian. Learning and evolutionary parameter optimization. AI Commun 15 (2002) 61-74
26. Matsumoto S., Iwakawa R., Kohno T., Suzuki K., Matsuno Y., Yamamoto S., et al. Frequent EGFR mutations in noninvasive bronchioloalveolar carcinoma. Int J Cancer 118 (2006) 2498-2504
27. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., et al. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23 (2005) 857-865
28. Packeisen J., Nakachi K., Boecker W., Brandt B., and Buerger H. Cytogenetic differences in breast cancer samples between German and Japanese patients. J Clin Pathol 58 (2005) 1101-1103
29. D'Haese J.G., Tsukasaki K., Cremer F.W., Fischer C., Bartram C.R., and Jauch A. Chromosomal aberrations in follicular non-Hodgkin lymphomas of Japanese patients, detected with comparative genomic hybridization and polymerase chain reaction analysis. Cancer Genet Cytogenet 162 (2005) 107-114
30. Goeze A., Schluns K., Wolf G., Thasler Z., Petersen S., and Petersen I. Chromosomal imbalances of primary and metastatic lung adenocarcinomas. J Pathol 196 (2002) 8-16
31. Bigner S.H., Wong A.J., Mark J., Muhlbaier L.H., Kinzler K.W., Vogelstein B., et al. Relationship between gene amplification and chromosomal deviations in malignant human gliomas. Cancer Genet Cytogenet 29 (1987) 165-170
32. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 65 (2005) 226-235
33. Shibata T., Uryu S., Kokubu A., Hosoda F., Ohki M., Sakiyama T., et al. Genetic classification of lung adenocarcinoma based on array-based comparative genomic hybridization analysis: its association with clinicopathologic features. Clin Cancer Res 11 (2005) 6177-6185
34. Sunwoo J.B., Sun P.C., Gupta V.K., Schmidt A.P., El-Mofty S., and Scholnick S.B. Localization of a putative tumor suppressor gene in the sub-telomeric region of chromosome 8p. Oncogene 18 (1999) 2651-2655
35. Bullard R.S., Gibson W., Bose S.K., Belgrave J.K., Eaddy A.C., Wright C.J., et al. Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer. Mol Immunol 45 (2008) 839-848
36. Shinojima N., Tada K., Shiraishi S., Kamiryo T., Kochi M., Nakamura H., et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res 63 (2003) 6962-6970
37. Suzuki M., Shigematsu H., Hiroshima K., Iizasa T., Nakatani Y., Minna J.D., et al. Epidermal growth factor receptor expression status in lung cancer correlates with its mutation. Hum Pathol 36 (2005) 1127-1134
38. Suzuki S., Dobashi Y., Sakurai H., Nishikawa K., Hanawa M., and Ooi A. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas. An immunohistochemical and fluorescence in situ hybridization study. Cancer 103 (2005) 1265-1273
39. Bruns C.J., Liu W., Davis D.W., Shaheen R.M., McConkey D.J., Wilson M.R., et al. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Cancer 89 (2000) 488-499
40. Herbst R.S., Johnson D.H., Mininberg E., Carbone D.P., Henderson T., Kim E.S., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the Her-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small cell lung cancer. J Clin Oncol 23 (2005) 2544-2555
41. Angulo B., Suarez-Gauthier A., Lopez-Rios F., Medina P., Conde E., Tang M., et al. Expression signatures in lung cancer reveal a profile for EGFR-mutant tumours and identify selective PIK3CA overexpression by gene amplification. J Pathol 214 (2007) 347-356